Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Ifenprodil Tartrate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Algernon Reports 93% Cough Suppression With Ifenprodil
    Algernon Reports 93% Cough Suppression With Ifenprodil

    16 Jul 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/07/16/2913704/0/en/Algernon-Pharmaceuticals-Reports-Results-of-Study-Showing-93-Cough-Suppression-with-Ifenprodil.html

    GLOBENEWSWIRE
    16 Jul 2024
    Share Share
    Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent
    Algernon Pharmaceuticals Announces Notice of Allowance for Ifenprodil Patent

    11 Jan 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2024/01/11/2807778/0/en/Algernon-Pharmaceuticals-Announces-Notice-of-Allowance-for-Ifenprodil-Patent-in-Japan-for-Idiopathic-Pulmonary-Fibrosis.html

    GLOBENEWSWIRE
    11 Jan 2024
    Share Share
    Algernon to Present Phase 2 Ifenprodil Cough Data at Conference
    Algernon to Present Phase 2 Ifenprodil Cough Data at Conference

    06 Jun 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/06/06/2682659/0/en/Algernon-Pharmaceuticals-to-Present-Phase-2-Ifenprodil-Cough-Data-at-the-2023-American-Cough-Conference.html

    GLOBENEWSWIRE
    06 Jun 2023
    Share Share
    Algernon Announces Plans for 180 Patient Ph 2b Chronic Cough Study of Ifenprodil
    Algernon Announces Plans for 180 Patient Ph 2b Chronic Cough Study of Ifenprodil

    09 Jan 2023

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2023/01/09/2585006/0/en/Algernon-Pharmaceuticals-Announces-Plans-for-a-180-Patient-Phase-2b-Chronic-Cough-Study-of-Ifenprodil.html

    GLOBENEWSWIRE
    09 Jan 2023
    Share Share
    Algernon Receives U.S. FDA Orphan Drug Designation for Ifenprodil
    Algernon Receives U.S. FDA Orphan Drug Designation for Ifenprodil

    05 Dec 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2022/12/05/2567239/0/en/Algernon-Pharmaceuticals-Receives-U-S-FDA-Orphan-Drug-Designation-for-Ifenprodil-for-the-Treatment-of-Idiopathic-Pulmonary-Fibrosis.html

    GLOBENEWSWIRE
    05 Dec 2022
    Share Share
    FDA grants orphan drug designation to Algernon's ifenprodil, exclusivity unclear
    FDA grants orphan drug designation to Algernon's ifenprodil, exclusivity unclear

    05 Dec 2022

    // Nicole DeFeudis ENDPTS

    https://endpts.com/fda-grants-orphan-drug-designation-to-algernons-ifenprodil-while-exclusivity-remains-unclear/

    Nicole DeFeudis ENDPTS
    05 Dec 2022
    Share Share